Tags

Type your tag names separated by a space and hit enter

[An experimental study on the effect of azithromycin treatment in bleomycin-induced pulmonary fibrosis of rats].
Zhonghua Nei Ke Za Zhi. 1999 Oct; 38(10):677-80.ZN

Abstract

OBJECTIVE

To evaluate the therapeutic effects and mechanism of azithromycin treatment in bleomycin-induced pulmonary fibrosis of rats.

METHODS

Animal model of bleomycin-A5-induced pulmonary fibrosis was established in rats.36 animal models were divided into two groups: a bleomycin-induced pulmonary fibrosis group and a azithromycin group in which the animal models were treated with azithromycin (80 mg/kg once a day for three continuous days in a week). The animals of the two groups were killed at the first,second and fourth week respectively. Another six rats constituted a normal control group, instillated withsaline intratracheally and killed at the first week. Pathological changes activity of nuclear factor kappaB (NF-kappaB) of alveolar macrophage, cytokine tumor necrosis factor (TNF) alpha, transforming growth factor-beta (TGF-beta) mRNA expression and protein levels of alveolar macrophage and lung tissue were studied or measured.

RESULTS

Amelioration of alveolitis and lung fibrosis after treatment with azithromycin was shown in pathological section (P < 0.05). The activity of NF-kappaB was significantly higher in one-week pulmonary fibrosis model than that in normal control and its level in alveolar macrophage reduced (67.2%) after treatment with azithromycin. The level of protein and mRNA of TNFalpha, TGF-beta in lung tissue and alveolar macrophage was increased in the early stage of pulmonary fibrosis and reduced after treatment with azithromycin (P < 0.05).

CONCLUSION

It is suggested that azithromycin might be a therapeutic drug for pulmonary fibrosis in the future. Azithromycin reduced the degree of alveolitis and fibrosis through inhibition of the activity of NF-kappaB and the expression of TNFalpha, TGF-beta mRNA and lowering the level of protein in alveolar macrophage and lung tissue in the early stage of pulmonary fibrosis. This might be one of the mechanisms of azithromycin treatment in pulmonary fibrosis.

Authors+Show Affiliations

Department of Pulmonary Medicine, The First Hospital, Beijing Medical University, Beijing 100034.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

11798706

Citation

Chen, J, et al. "[An Experimental Study On the Effect of Azithromycin Treatment in Bleomycin-induced Pulmonary Fibrosis of Rats]." Zhonghua Nei Ke Za Zhi, vol. 38, no. 10, 1999, pp. 677-80.
Chen J, He B, Li Y, et al. [An experimental study on the effect of azithromycin treatment in bleomycin-induced pulmonary fibrosis of rats]. Zhonghua Nei Ke Za Zhi. 1999;38(10):677-80.
Chen, J., He, B., Li, Y., Wang, G., & Zhang, W. (1999). [An experimental study on the effect of azithromycin treatment in bleomycin-induced pulmonary fibrosis of rats]. Zhonghua Nei Ke Za Zhi, 38(10), 677-80.
Chen J, et al. [An Experimental Study On the Effect of Azithromycin Treatment in Bleomycin-induced Pulmonary Fibrosis of Rats]. Zhonghua Nei Ke Za Zhi. 1999;38(10):677-80. PubMed PMID: 11798706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [An experimental study on the effect of azithromycin treatment in bleomycin-induced pulmonary fibrosis of rats]. AU - Chen,J, AU - He,B, AU - Li,Y, AU - Wang,G, AU - Zhang,W, PY - 2002/1/19/pubmed PY - 2004/10/8/medline PY - 2002/1/19/entrez SP - 677 EP - 80 JF - Zhonghua nei ke za zhi JO - Zhonghua Nei Ke Za Zhi VL - 38 IS - 10 N2 - OBJECTIVE: To evaluate the therapeutic effects and mechanism of azithromycin treatment in bleomycin-induced pulmonary fibrosis of rats. METHODS: Animal model of bleomycin-A5-induced pulmonary fibrosis was established in rats.36 animal models were divided into two groups: a bleomycin-induced pulmonary fibrosis group and a azithromycin group in which the animal models were treated with azithromycin (80 mg/kg once a day for three continuous days in a week). The animals of the two groups were killed at the first,second and fourth week respectively. Another six rats constituted a normal control group, instillated withsaline intratracheally and killed at the first week. Pathological changes activity of nuclear factor kappaB (NF-kappaB) of alveolar macrophage, cytokine tumor necrosis factor (TNF) alpha, transforming growth factor-beta (TGF-beta) mRNA expression and protein levels of alveolar macrophage and lung tissue were studied or measured. RESULTS: Amelioration of alveolitis and lung fibrosis after treatment with azithromycin was shown in pathological section (P < 0.05). The activity of NF-kappaB was significantly higher in one-week pulmonary fibrosis model than that in normal control and its level in alveolar macrophage reduced (67.2%) after treatment with azithromycin. The level of protein and mRNA of TNFalpha, TGF-beta in lung tissue and alveolar macrophage was increased in the early stage of pulmonary fibrosis and reduced after treatment with azithromycin (P < 0.05). CONCLUSION: It is suggested that azithromycin might be a therapeutic drug for pulmonary fibrosis in the future. Azithromycin reduced the degree of alveolitis and fibrosis through inhibition of the activity of NF-kappaB and the expression of TNFalpha, TGF-beta mRNA and lowering the level of protein in alveolar macrophage and lung tissue in the early stage of pulmonary fibrosis. This might be one of the mechanisms of azithromycin treatment in pulmonary fibrosis. SN - 0578-1426 UR - https://www.unboundmedicine.com/medline/citation/11798706/[An_experimental_study_on_the_effect_of_azithromycin_treatment_in_bleomycin_induced_pulmonary_fibrosis_of_rats]_ L2 - https://medlineplus.gov/pulmonaryfibrosis.html DB - PRIME DP - Unbound Medicine ER -